Dupixent® (dupilumab) Is the First and Only Biologic to Achieve Significant Improvements in Disease Remission and Symptoms in Bullous Pemphigoid (BP) Positive Pivotal Trial
September 11, 2024 00:59 ET
|
Regeneron Pharmaceuticals, Inc.
Trial met the primary and all key secondary endpoints in adults with moderate-to-severe disease; five times more patients achieved sustained disease remission with Dupixent than placebo Dupixent is...
Libtayo® (cemiplimab) Demonstrates Durable Survival Benefit at Five Years in Advanced Non-small Cell Lung Cancer
September 09, 2024 17:00 ET
|
Regeneron Pharmaceuticals, Inc.
Late-breaking data at WCLC show Libtayo monotherapy nearly doubled median overall survival and reduced the risks of death and disease progression by 41% and 50%, respectively, compared to chemotherapy...
Regeneron to Highlight Progress Across Its Differentiated Oncology Portfolio and Pipeline at WCLC and ESMO
September 09, 2024 07:00 ET
|
Regeneron Pharmaceuticals, Inc.
At WCLC, five-year survival data to be presented on Libtayo (PD-1 inhibitor) first-line monotherapy in advanced non-small cell lung cancer At ESMO, longer-term results with investigational fianlimab...
Ordspono™ (odronextamab) Approved in the European Union for the Treatment of Relapsed/Refractory Follicular Lymphoma and Diffuse Large B-cell Lymphoma
August 26, 2024 07:00 ET
|
Regeneron Pharmaceuticals, Inc.
Approval of Ordspono is based on data demonstrating robust and durable responses in both relapsed/refractory follicular lymphoma and diffuse large B-cell lymphoma, including in the post-CAR-T setting ...
Latest Dupixent® (dupilumab) and Itepekimab Data at ERS Highlight Scientific Innovation and Leadership in Respiratory Diseases
August 26, 2024 01:00 ET
|
Regeneron Pharmaceuticals, Inc.
20 abstracts, including 4 oral presentations, offer new treatment insights for chronic obstructive pulmonary disease (COPD), asthma and chronic rhinosinusitis with nasal polyps (CRSwNP) Data from...
Regeneron Provides Update on Biologics License Application for Linvoseltamab
August 20, 2024 18:45 ET
|
Regeneron Pharmaceuticals, Inc.
TARRYTOWN, N.Y., Aug. 20, 2024 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the U.S. Food and Drug Administration (FDA) has issued a Complete Response...
Regeneron Announces Investor Conference Presentations and Oncology Investor Webcast
August 07, 2024 16:05 ET
|
Regeneron Pharmaceuticals, Inc.
TARRYTOWN, N.Y., Aug. 07, 2024 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) announces the following September 2024 investor events: Investor Conference Presentations • Morgan...
Regeneron Reports Second Quarter 2024 Financial and Operating Results
August 01, 2024 06:30 ET
|
Regeneron Pharmaceuticals, Inc.
Second quarter 2024 revenues increased 12% to $3.55 billion versus second quarter 2023Second quarter 2024 Dupixent® global net sales (recorded by Sanofi) increased 27% to $3.56 billion versus second...
Regeneron Announces the 2024 Winners of the Regeneron Prize for Creative Innovation
July 31, 2024 07:30 ET
|
Regeneron Pharmaceuticals, Inc.
TARRYTOWN, N.Y., July 31, 2024 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced the winners of the 12th annual Regeneron Prize for Creative Innovation (the...
Dupixent® (dupilumab) Approved in the European Union as the First-ever Targeted Therapy for Patients with COPD
July 03, 2024 01:00 ET
|
Regeneron Pharmaceuticals, Inc.
First-in-world approval of Dupixent for adults with uncontrolled COPD with raised blood eosinophils based on two landmark Phase 3 trials showing Dupixent significantly reduced exacerbations, improved...